Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
44 /100
MEDIUM RISK
Score updated Oct 13, 2026

MYGN — Myriad Genetics, Inc. Dilution Risk Tracker

Track MYGN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track MYGN — Get alerts when the score changes →

As of October 13, 2026, Myriad Genetics, Inc. (MYGN) has a DilutionWatch DilutionScore of 44/100, rated MEDIUM dilution risk. Myriad Genetics, Inc. has a market capitalization of $401.73M, 95.65M shares outstanding, 205 institutional holders tracked. Stored dilution-related fields include shelf registration capacity of $200.00M, ATM program capacity of $200.00M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
65
💰 Cash Runway
40
📊 Float Risk
5
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

⛅
Watch
Minor dilution signals detected
model est. 19%
💰 Capital Raise model 38%
• Active shelf registration ($200M, 50% of market cap)
• Active ATM program with $200M remaining capacity
🔔 Track MYGN — Get forecast alerts →

Market Data

Market Cap$401.73M
Shares Outstanding95.65M
Float85.99M
Cash$115.20M
Debt$319.90M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore44/100DilutionWatch score record
Shares Outstanding95.65MVerified float table or market cache
Public Float85.99MVerified float table or market cache
Market Cap$401.73MMarket data cache
Cash Runway16.5 monthsDilutionWatch score inputs
Shelf Capacity$200.00MSEC-derived dilution fields
ATM Capacity$200.00MSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 5.

Recent SEC source mix: 4 2, 424B3 1, EFFECT 1, S-3 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 145.3% shares (2026Q1 vs prior)
205 institutional holders · 228.54M shares
#1 ORBIMED ADVISORS LLC 125.00M shares
#2 MORGAN STANLEY 10.39M shares
#3 BlackRock, Inc. 8.89M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest8.55M
Days to Cover4.2
% of Float9.9%
FINRA data as of Sep 30, 2026

Recent SEC Activity

424B3 ATM 2026-03-04
EFFECT EFFECT 2026-03-04
4 INSIDER TRANSACTION 2026-03-02
4 INSIDER TRANSACTION 2026-02-27
S-3 SHELF 2026-02-24
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual MYGN Dilution Snapshot

Myriad Genetics, Inc. (MYGN) has a DilutionScore of 44/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

MYGN's DilutionScore is currently 44/100 (Medium risk), with 4 score changes tracked over 89 days. The score deteriorated from 45/100 (Medium risk).

Period Score Risk Level Duration
Oct 13, 202644/100MEDIUM1 day
Oct 10 – Oct 12, 202645/100MEDIUM3 days
Sep 30 – Oct 09, 202650/100MEDIUM10 days
Jul 17 – Sep 29, 202649/100MEDIUM74 days
Jul 16, 202650/100MEDIUM1 day

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

MYGN shares outstanding have increased 1.0% from 93.51M (Mar 2026) to 94.45M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 09, 202694.45M85.99M▲ 0.05%
May 07, 202694.45M85.95M▲ 0.95%
Apr 03, 202693.51M85.14M▲ 8.17%
Mar 26, 202693.51M78.71M▼ 0.85%
Mar 19, 202693.51M79.38M▲ 0.03%
Mar 11, 202693.51M79.36M▼ 0.13%
Mar 09, 202693.51M79.47M▲ 0.04%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track MYGN Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment MYGN files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking MYGN — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for MYGN
MYGN FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.